Drug Insights

Your Ultimate Guide to Finding Diclofenac sodium on Synapse

23 February 2024
2 min read

Diclofenac sodium, a benzene-acetic acid derivative, is a nonsteroidal anti-inflammatory drug (NSAID) ,has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Diclofenac sodium, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). The FDA approved diclofenac sodium as VOLTAREN on July 28, 1988, and its originator was the Ciba-Geigy Corporation, which is now a part of Novartis. This drug has been used for many years to manage a wide range of painful conditions and is widely available in both prescription and over-the-counter formulations. Click on the image below to begin the exploration journey of Diclofenac sodium through the Synapse database!

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

US Approves TAGRISSO® and Chemotherapy Combo for Advanced EGFR-Mutated Lung Cancer
Latest Hotspot
3 min read
US Approves TAGRISSO® and Chemotherapy Combo for Advanced EGFR-Mutated Lung Cancer
23 February 2024
US authorities greenlight a combined treatment of TAGRISSO® (osimertinib) and chemotherapy for individuals battling advanced lung cancer with EGFR mutations.
Read →
Datopotamab Deruxtecan: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GU
Datopotamab Deruxtecan: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GU
23 February 2024
Datopotamab deruxtecan (Dato-DXd) is an ADC comprising a humanized anti-TROP2 IgG1 monoclonal antibody bonded to a potent topoisomerase I inhibitor through a stable, tumor-specific, cleavable tetrapeptide linker.
Read →
U.S. Greenlights Early Review of New Treatment for Advanced Non-Squamous NSCLC
Latest Hotspot
3 min read
U.S. Greenlights Early Review of New Treatment for Advanced Non-Squamous NSCLC
23 February 2024
U.S. Authorities Approve Review for Deruxtecan-Datopotamab Treatment Submission for Earlier Managed Advanced Non-Squamous NSCLC Cases.
Read →
Explore Tadalafil on Synapse: Tips and Tricks for Better Search Results
Drug Insights
2 min read
Explore Tadalafil on Synapse: Tips and Tricks for Better Search Results
23 February 2024
Tadalafil, sold as Cialis, is a PDE5 inhibitor, similar to sildenafil (Viagra) and vardenafil (Levitra).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.